α-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia

Journal of Pediatric Hematology/Oncology

Volumn 24, Issue 1, 2002, Pages 18-22

  Millot, Frédéric ^a   Brice, Pauline ^a   Philippe, Noel ^a   Thyss, Antoine ^a   Demeoq, François ^a   Wetterwald, Marc ^a   Boccara, Jean Françoise ^a   Vilque, Jean Pierre ^a   Guyotat, Denis ^a   Guilhot, Joelle ^a   Guilhot, François ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Children; Chronic myelogenous leukemia; Cytosine arabinoside; Interferon

Indexed keywords

ALPHA2B INTERFERON; CYTARABINE; HYDROXYUREA;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; ASTHENIA; ATRIOVENTRICULAR BLOCK; BLOOD TOXICITY; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; FEMALE; FEVER; FOLLOW UP; HUMAN; MALE; MENTAL DISEASE; NAUSEA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CYTARABINE; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; LEUKOCYTE COUNT; METAPHASE; SPLEEN; TREATMENT OUTCOME;

EID: 0036157969     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200201000-00006     Document Type: Article

References (25)

1. Chronic leukemias of childhood
2. Hyperleukocytosis and leukostasis: Common features of childhood chronic myelogenous leukemia
3. BCR-ABL rearrangements in children with Philadelphia chromosome positive chronic myelogenous leukemia
4. Philadelphia chromosome positive chronic myelocytic leukemia in children: Survival and prognostic factors
5. Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia
6. Long-term follow-up of the Italian trial of interferon-α versus conventional chemotherapy in chronic myeloid leukemia
7. UK Medical Research Council randomised, multicentre trial of interferon-α for chronic myeloid leukemia: Improved survival irrespective of cytogenetic response
8. Cytogenetic remissions in chronic myelogenous leukemia using interferon-alpha-2a and hydroxyurea with or without low-dose cytosine arabinoside
9. Interferon-alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
10. Survival of children with chronic myelogenous leukemia
11. Prognostic discrimination in good-risk chronic granulocytic leukemia
12. Comparative analysis of the impact of risk profile and the drug therapy on survival in CML using Sokal's index and a new score
13. Response to alpha-interferon in children with Philadelphia-positive chronic myelocytic leukemia
14. Classification of chronic myelocytic leukemia in children
15. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology
16. Bone marrow transplantation in comparison with conventional therapy in children with adult-type chronic myelogenous leukemia
17. Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive myelogenous leukemia in children
18. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
19. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy
20. Combined recombinant human interferon alpha and cytotoxic agents studied in a clonogenic assay
21. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-α and low doses cytarabine
22. Combined interferon alpha-2a and cytosine aritbinoside as first-line treatment for chronic myeloid leukemia
23. Interferon alpha 2a and LD ara-C for treatment of patients with CML: Results of the Austrian multicenter phase II study
24. Cardiotoxicity of interferon: A review
25. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl-positive cells